MX2022010161A - Proteínas biespecíficas anti-her2 diseñadas. - Google Patents
Proteínas biespecíficas anti-her2 diseñadas.Info
- Publication number
- MX2022010161A MX2022010161A MX2022010161A MX2022010161A MX2022010161A MX 2022010161 A MX2022010161 A MX 2022010161A MX 2022010161 A MX2022010161 A MX 2022010161A MX 2022010161 A MX2022010161 A MX 2022010161A MX 2022010161 A MX2022010161 A MX 2022010161A
- Authority
- MX
- Mexico
- Prior art keywords
- subdomain
- bispecific proteins
- engineered anti
- her2 bispecific
- human her2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978758P | 2020-02-19 | 2020-02-19 | |
| PCT/US2021/018705 WO2021168194A1 (en) | 2020-02-19 | 2021-02-19 | Engineered anti-her2 bispecific proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010161A true MX2022010161A (es) | 2022-11-07 |
Family
ID=77391704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010161A MX2022010161A (es) | 2020-02-19 | 2021-02-19 | Proteínas biespecíficas anti-her2 diseñadas. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230192887A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4181950A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023514371A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220156526A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115361972A (cg-RX-API-DMAC7.html) |
| AR (1) | AR121384A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021224200A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022016232A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3170338A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL295729A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022010161A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202144431A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021168194A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| US20240392035A1 (en) * | 2021-08-25 | 2024-11-28 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| CN120077064A (zh) * | 2022-08-05 | 2025-05-30 | 詹森生物科技公司 | 用于治疗脑肿瘤的转铁蛋白受体结合蛋白 |
| EP4565331A1 (en) * | 2022-08-05 | 2025-06-11 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047327A2 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| US9101674B2 (en) * | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
| LT3074424T (lt) * | 2013-11-27 | 2025-05-26 | Zymeworks Bc Inc. | Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2 |
| WO2015095412A1 (en) * | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| JP6510532B2 (ja) * | 2013-12-20 | 2019-05-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性her2抗体及び使用方法 |
| CA2943299A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Bispecific her2 antibodies |
| US10717783B2 (en) * | 2014-12-22 | 2020-07-21 | Zeren Gao | Bispecific tetravalent antibodies and methods of making and using thereof |
| JP7021955B2 (ja) * | 2015-06-24 | 2022-03-03 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Her2及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法 |
| CA3053381A1 (en) * | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Engineered polypeptides |
| WO2019032955A1 (en) * | 2017-08-10 | 2019-02-14 | Denali Therapeutics Inc. | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
| RU2018111298A (ru) * | 2018-03-29 | 2019-10-01 | Закрытое Акционерное Общество "Биокад" | Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека |
| EP3840781A1 (en) * | 2018-08-22 | 2021-06-30 | Denali Therapeutics Inc. | Anti-her2 polypeptides and methods of use thereof |
-
2021
- 2021-02-19 CA CA3170338A patent/CA3170338A1/en active Pending
- 2021-02-19 AU AU2021224200A patent/AU2021224200A1/en not_active Abandoned
- 2021-02-19 AR ARP210100440A patent/AR121384A1/es unknown
- 2021-02-19 MX MX2022010161A patent/MX2022010161A/es unknown
- 2021-02-19 EP EP21756590.2A patent/EP4181950A4/en active Pending
- 2021-02-19 IL IL295729A patent/IL295729A/en unknown
- 2021-02-19 WO PCT/US2021/018705 patent/WO2021168194A1/en not_active Ceased
- 2021-02-19 TW TW110105842A patent/TW202144431A/zh unknown
- 2021-02-19 KR KR1020227028989A patent/KR20220156526A/ko not_active Ceased
- 2021-02-19 BR BR112022016232A patent/BR112022016232A2/pt unknown
- 2021-02-19 CN CN202180027050.7A patent/CN115361972A/zh active Pending
- 2021-02-19 JP JP2022549653A patent/JP2023514371A/ja active Pending
-
2022
- 2022-08-11 US US17/819,182 patent/US20230192887A1/en active Pending
-
2026
- 2026-02-05 JP JP2026017499A patent/JP2026086568A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4181950A4 (en) | 2024-07-17 |
| KR20220156526A (ko) | 2022-11-25 |
| JP2026086568A (ja) | 2026-05-26 |
| IL295729A (en) | 2022-10-01 |
| TW202144431A (zh) | 2021-12-01 |
| US20230192887A1 (en) | 2023-06-22 |
| CA3170338A1 (en) | 2021-08-26 |
| EP4181950A1 (en) | 2023-05-24 |
| AU2021224200A1 (en) | 2022-09-08 |
| BR112022016232A2 (pt) | 2022-11-16 |
| CN115361972A (zh) | 2022-11-18 |
| AR121384A1 (es) | 2022-06-01 |
| WO2021168194A1 (en) | 2021-08-26 |
| JP2023514371A (ja) | 2023-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552122A1 (en) | Antibodies and fusion proteins that bind to ccr8 and uses thereof | |
| MX2023010499A (es) | Anticuerpos heterodimericos que se unen a cd3 y cldn6. | |
| MX2023005375A (es) | Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina. | |
| MX2021015888A (es) | Fusión de un anticuerpo que se une a cea y 4-1bbl. | |
| MX2024005712A (es) | Moleculas de anticuerpo y conjugados. | |
| SA519402358B1 (ar) | Ccr7 مترافقات عقار جسم مضاد لـ | |
| MX2024002238A (es) | Anticuerpos anti-ccr8 y uso de los mismos. | |
| PH12020552221A1 (en) | Anti-pd-1 antibodies and uses thereof | |
| BR112022016232A2 (pt) | Proteínas biespecíficas anti-her2 manipuladas | |
| MX2020002880A (es) | Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1). | |
| MY203469A (en) | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy | |
| MX2020012607A (es) | Anticuerpos especificos para gucy2c y sus usos. | |
| MX2021014193A (es) | Moleculas de enlace biespecificas anti-ror1/anti-cd3. | |
| MX337052B (es) | Peptidos que se enlazan a fosfatidiletanolamina y sus usos en el tratamiento de infecciones virales y del cancer. | |
| WO2022051591A3 (en) | Nectin-4 antibodies and uses thereof | |
| MX2024005392A (es) | Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3. | |
| MY176475A (en) | Human antibodies to pd-1 | |
| MX2020004410A (es) | Anticuerpos biespecificos con funciones efectoras reducidas. | |
| MX2023014645A (es) | Proteinas acopladoras de celulas nk de union a nkp46 especificas de cd20. | |
| WO2021226204A3 (en) | Anti-dll3 antibodies and methods of use | |
| WO2008070042A3 (en) | High potency recombinant antibodies, methods for producing them and use in cancer therapy | |
| WO2021263227A3 (en) | Anti-nme antibody and method of treating cancer or cancer metastasis | |
| CR20230374A (es) | Anticuerpos monoclonales anti-gprc5d y usos de los mismos | |
| MY204733A (en) | Anti-pd-l1 antibodies and use thereof | |
| MX2025000124A (es) | Combinaciones de proteinas de fusion a fc heterodimericas il15/il15r alfa y anticuerpos biespecificos fcrh5xcd3 para el tratamiento de tipos de cancer de sangre |